Upcoming Webinars

 

Leveraging the Value of Clinical Outcomes in DMD for Decision Making
Wednesday, December 4, 2024
11:00AM EST | 3:00PM UTC | 5:00PM CEST

MASLD/MASH: Clinical and Economic Findings from 40-year Follow-Up Data
Tuesday, December 10, 2024
9:00AM EST | 1:00PM UTC | 3:00PM CEST

Most Recent


The Burden of Time: MS Treatment and Socio-Economic Impact Reduction

Oct 2024

The webinar will present a novel study that explores the impact of Multiple Sclerosis (MS) on patients’ health and overall well-being, highlighting the importance of early access to disease-modifying treatments (DMTs) with convenient administration.

IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings

Oct 2024

Drs. Inma Hernandez and Sean D. Sullivan will compare the recently published Medicare Maximum Fair Prices (MFPs) with net prices before negotiation to discuss the potential magnitude of savings achieved by negotiation. Drs. John O’Brien of the National Pharmaceutical Council and Greg Daniel of Eli Lilly will provide additional context for the MFPs and the estimated cost savings projections. This session will be highly relevant for professionals and researchers in market access, pricing, and HEOR.

Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

Oct 2024

This webinar will benefit stakeholders involved in health technology assessment (HTA), artificial intelligence (AI) development, and AI regulation by providing a comprehensive debate on the use of AI in Joint Clinical Assessments (JCAs).

Global Perspective on Inequality Aversion: Methods and Learnings

Oct 2024

Inequality aversion represents the degree of concern for reducing a specified inequality, which can also be interpreted as the value that a given stakeholder places on changes in health inequalities. Information on aversion to inequality is often expressed as inequality aversion parameters, such as the Atkinson index. Such parameters can be applied to forms of equity analysis, including distributional cost-effectiveness analysis (DCEA) that enables researchers to evaluate both the equity and effectiveness of healthcare interventions and the broader impacts of healthcare decisions. Incorporating inequality aversion parameters in DCEA facilitates the exploration of the consequences of different social value judgments when comparing policy options that involve trade-offs between improving total health and reducing health inequality.

Patient Involvement in Value and Health Technology Assessment (V/HTA)

Oct 2024

Patient involvement in HTA and broader value assessment is an essential aspect of promoting patient-centered decision-making in healthcare. Historically, patient involvement in these processes has been limited, leading to decisions that may not fully consider patient perspectives, preferences, and values. However, without offering any recognizable value to patients, health technologies may fail to generate value in the healthcare system. Therefore, the objective of this webinar is to emphasize the significance of patient involvement in HTA and broader value assessment and to delve into the challenges associated with it, while also presenting potential solutions.

Conducting Research and Survey Studies in Hard-to-Reach Populations

Oct 2024

The patient is at the center of survey, health preference, and patient-reported outcome (PRO) research. By their nature, hard-to-reach populations are difficult to engage in health research, as they may not be recruitable through commonly used channels or may need additional assistance with survey tasks or different modes of administration for PROs and preference tasks. With survey, preference and PRO research increasingly being conducted online due to time and budgetary efficiencies, the likelihood of successfully involving hard-to-reach populations becomes ever smaller. But when the research question concerns the hard-to-reach populations, how can we ensure that the results reflect their views?

Clinical Outcomes



Are Clinical Outcome Assessments Sufficiently Valued?

May 2024

The aim of the webinar is to increase awareness of the challenges associated with generating PRO data and its value to different stakeholders and generate discussion to inform potential solutions to these challenges. Finally, the webinar will provide information about the content of the SISAQOL-IMI recommendations and how they can be used.

Beyond the Boundaries of RCT Data: Connecting Trials to the Real-World

Apr 2024

Join Inovalon’s experts as they discuss the power of combining RCT with real-world data, through innovative data-linking techniques, to transform understanding of the patient journey to uncover invaluable insights into clinical and economic outcomes in the real-world.

Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.


Economic Evaluation



Global Perspective on Inequality Aversion: Methods and Learnings

Oct 2024

Inequality aversion represents the degree of concern for reducing a specified inequality, which can also be interpreted as the value that a given stakeholder places on changes in health inequalities. Information on aversion to inequality is often expressed as inequality aversion parameters, such as the Atkinson index. Such parameters can be applied to forms of equity analysis, including distributional cost-effectiveness analysis (DCEA) that enables researchers to evaluate both the equity and effectiveness of healthcare interventions and the broader impacts of healthcare decisions. Incorporating inequality aversion parameters in DCEA facilitates the exploration of the consequences of different social value judgments when comparing policy options that involve trade-offs between improving total health and reducing health inequality.

Measuring the Indirect Costs Driving Financial Toxicity in Oncology

Apr 2024

In this webinar, experts will characterize financial toxicity from the patient perspective, suggest potential frameworks for incorporation of financial toxicity into economic evaluation, and discuss areas where further research is necessary.

Driving Health Outcomes: Exploring Value-Based Procurement

Aug 2023

Value-Based Procurement (VBP) is a critical element of a value-based healthcare system, offering a transformative purchase approach that addresses underlying barriers to access to innovative treatments. Unlike the traditional procurement methods that focus primarily on cost containment, VBP considers multiple factors, including the unique circumstances of each country, such as local disease burden, health priorities, infrastructure, supply chain, ability to pay for healthcare, and budget processes.

Economic Evaluation of Digital Health Technologies

Jul 2023

This webinar aims to provide insights into the economic evaluation of digital health technology, which presents unique challenges compared to pharmaceuticals, healthcare services, and medical devices. In this webinar, you will learn about the current role of health economics and outcomes research in assessing the value of digital health technologies, as well as the impact of digital health interventions in today’s healthcare systems.


Health Technology Assessment



Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

Oct 2024

This webinar will benefit stakeholders involved in health technology assessment (HTA), artificial intelligence (AI) development, and AI regulation by providing a comprehensive debate on the use of AI in Joint Clinical Assessments (JCAs).

Patient Involvement in Value and Health Technology Assessment (V/HTA)

Oct 2024

Patient involvement in HTA and broader value assessment is an essential aspect of promoting patient-centered decision-making in healthcare. Historically, patient involvement in these processes has been limited, leading to decisions that may not fully consider patient perspectives, preferences, and values. However, without offering any recognizable value to patients, health technologies may fail to generate value in the healthcare system. Therefore, the objective of this webinar is to emphasize the significance of patient involvement in HTA and broader value assessment and to delve into the challenges associated with it, while also presenting potential solutions.

Transferability of Data and Methods to Central and Eastern Europe

Sep 2024

The aim of this webinar is to discuss the questions: What are the main barriers which prevent transferring data and methods in CEE, originally generated in Western Europe? What are the proposed solutions to overcome these barriers and opportunities?

Moving Toward Universal Health Coverage in Africa: The Role of HTA

Aug 2024

Most African countries have integrated universal health coverage (UHC) as a goal in their national health strategies. To strengthen commitment and accelerate progress towards UHC, it is important for countries to effectively address challenges associated with expanded healthcare utilization. In this webinar, experts from the Africa region will discuss the role of HTA for advancing UHC and share lessons on how to structure health systems to implement HTA and how to use HTA to inform UHC decision-making.


Real-World Data & Information Systems


Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation

Apr 2024

In this session, we'll discuss leveraging RWE to enhance diversity within clinical trials and expedite the translation of research findings into real-world clinical practice. Our expert panel will illuminate how RWE can address existing disparities in clinical trial participation, amplify the voices of underrepresented communities, and ultimately lead to more effective and equitable healthcare interventions.

Tokenization in Clinical Trials: Benefits and End-to-End Enablement

Dec 2023

This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets.

The Use of Real-World Evidence in HTA in Central and Eastern Europe

Sep 2023

This webinar will cover the opportunities and challenges of collecting real-world data (RWD) and generating real-world evidence (RWE) for making better decisions in healthcare, specifically in Health Technology Assessment (HTA).

Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Jul 2023

In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.


Patient-Centered Research



Conducting Research and Survey Studies in Hard-to-Reach Populations

Oct 2024

The patient is at the center of survey, health preference, and patient-reported outcome (PRO) research. By their nature, hard-to-reach populations are difficult to engage in health research, as they may not be recruitable through commonly used channels or may need additional assistance with survey tasks or different modes of administration for PROs and preference tasks. With survey, preference and PRO research increasingly being conducted online due to time and budgetary efficiencies, the likelihood of successfully involving hard-to-reach populations becomes ever smaller. But when the research question concerns the hard-to-reach populations, how can we ensure that the results reflect their views?

Innovative Uses of Technology to Advance Health Preference Research

Sep 2023

Stated preference surveys often involve communicating large volumes of complex and/or unfamiliar medical information to provide context for respondents. This webinar examines innovative uses of technology to advance discrete choice experiment (DCE) research within health preference research. They will explore the different technologies that can be integrated into preference surveys illustrating how technology can better inform and potentially engage respondents.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 3

Jul 2023

With the public comment period open until July 2023, this webinar will also present ISPOR members with the opportunity to ask questions and provide comments that will help inform ISPOR’s response on the draft guidance 4 document.

Clinical Trial Innovation: How Healthcare Technology is Evolving

Jun 2023

Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.

Medical Technologies



Digital Technologies for Health Systems: The African Experience

Dec 2023

This webinar focuses on important developments within the African continent. The main learning objectives are (1) to outline country experiences on rolling out digital health technologies, (2) discuss the role of big data analytics, and (3) describe the future prospects in the African context.

How to Drive Value in the Digital Transformation Era?

Sep 2023

The multi-stakeholder panel in this webinar will discuss how to strike the balance between openness and security in the process of health data collection for the successful value assessment regarding digital solutions.

Digital Endpoint Adoption: the How, What and Why

Feb 2023

Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.

On the Validity of Statistical Analyses with Privacy-Preserving Synthetic Data

Sep 2022

This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.

Methodical & Statistical Research



Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals

Oct 2024

This session will highlight practical use cases and best practices in applying AI to meet the demands of health technology assessments (HTA), health economics and outcomes research (HEOR) and surveillance activities.

External Control Arms - Application, Key Methods, and Acceptability

Oct 2023

This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.

Applications of Large Language Models for RWD Analytics

Oct 2023

In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.

Harnessing Horses and Zebras in Predictive Analytics: Methodological Considerations for Extreme Population Sizes in Real-World Evidence Generation

Sep 2023

This webinar is aimed at those who perform or use the results of real-world evidence (RWE) studies. It aims to describe the use of predictive analytics and machine learning for causal inference in the context of the extremes for disease populations: rare diseases and common conditions such as obesity.

Health Policy & Regulatory



The Burden of Time: MS Treatment and Socio-Economic Impact Reduction

Oct 2024

The webinar will present a novel study that explores the impact of Multiple Sclerosis (MS) on patients’ health and overall well-being, highlighting the importance of early access to disease-modifying treatments (DMTs) with convenient administration.

IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings

Oct 2024

Drs. Inma Hernandez and Sean D. Sullivan will compare the recently published Medicare Maximum Fair Prices (MFPs) with net prices before negotiation to discuss the potential magnitude of savings achieved by negotiation. Drs. John O’Brien of the National Pharmaceutical Council and Greg Daniel of Eli Lilly will provide additional context for the MFPs and the estimated cost savings projections. This session will be highly relevant for professionals and researchers in market access, pricing, and HEOR.

ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2024-2025?

Jun 2024

Hear from ISPOR’s Chief Science Officers, who will begin with the methods underlying the report, and then will discuss each of the Top 10 topics, the HEOR considerations related to each one, and how ISPOR members are engaged in them, and will conclude with a question and answer period.

The Global Socioeconomic Impact of Rare Diseases: A Call for Action

May 2024

The webinar will begin with an introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.

Study Approaches


Overcoming the Barriers of Open-Source Modeling

Jun 2024

The development and use of Open-Source Models (OSM) promises to increase the transparency and efficiency of health economic modelling endeavors. However, the number of open-source health economic models remains low. A recent survey of the ISPOR OSM Special Interest Group identified several barriers and opportunities for the development of OSM. However, little has been discussed in the literature on which barriers to OSM are most relevant for different stakeholder groups and how different stakeholders would address these barriers. Therefore, this webinar attempts to address this knowledge gap by bringing together stakeholders from different professional backgrounds.

Revolutionizing Systematic Reviews: Harnessing the Power of AI

May 2024

This webinar will provide a comprehensive overview of the current landscape of AI adoption in systematic reviews and showcase several state-of-the-art platforms revolutionizing the systematic review process.

Communicating High Value in Scientific Publications

Sep 2023

This webinar will introduce several strategies for communicating the results of your study. These strategies can be used regardless of study methodology (eg, chart reviews, database analyses, economic models) and publication type (eg, abstract, poster, manuscript, report). As the field of HEOR continues to proliferate, the need for timely, clear, concise publications has never been greater.

Introduction to Open-Source Modeling: R We There Yet?

Apr 2023

In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)


Epidemiology & Public Health


Assessing the Fiscal Burden of Obesity Using a Public Economic Framework

May 2024

Obesity is a health priority for many governments because of its impact on population health and its economic consequences. We aimed to measure the wider effects of obesity in Japan and Canada by using a government perspective framework that accounts for lost tax revenues and higher government spending on social benefit programs.

Challenges in Rare Disease Diagnostics: An Overview

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.

Health Equity in HEOR: Past, Present & Future Research Implications

Apr 2023

The webinar will provide an overview of past and current efforts in health equity, its role in health outcomes research, and its future implications in the field.

Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".


Specialized Treatment Areas


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.


Specific Diseases & Conditions


Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Implications of Matched Adjusted Indirect Treatment Comparisons in Rare Disease

Jun 2021

A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.

Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×